Salix Pharmaceuticals (SLXP) Tops Q2 EPS by 22c, Issues Mixed Guidance for Q3 and FY
Tweet Send to a Friend
Salix Pharmaceuticals, Inc. (Nasdaq: SLXP) reports a Q2 loss of $0.15, 22 cents better than the analyst estimate of ($0.37) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
